11Oct 2022
Dynamic monitoring of PD‐L1 and Ki67 in circulating tumor cells of metastatic non‐small cell lung cancer patients treated with pembrolizumab

Dynamic monitoring of PD‐L1 and Ki67 in circulating tumor cells of metastatic non‐small cell lung cancer patients treated with pembrolizumab

Programmed cell death protein ligand‐1 (PD‐L1) expression in non‐small cell lung cancer (NSCLC) tumours guides treatment selection. Patients displaying PMR (progression at first evaluation) were classified as progressive disease (PD), and those with clinical benefit as disease control (DC). In sequential samples of patients with durable use, a low Ki67 index was observed. The results suggest that monitoring PD‐L1 and Ki67 expression in CTCs of NSCLC patients treated with pembrolizumab may predict pembrolizumab efficacy.

  • #oncology

Like

Save

Share